Multigene signatures, including BRD4-interacting genes (e.g., EZH2, KIF20A, G6PD, and KIF2C), further highlight the biological complexity and heterogeneity of HCC and reinforce the need for integrated molecular approaches to complement clinicopathological staging [28,29,30]. Here, EZH2 is linked to hepatocellular carcinoma.